VintaCell™
Ready-to-use, high-producing
cGMP cell line.
VintaProcess™ generates high-yield, high-purity viral vectors
for clinical and commercial cell and gene therapies.
This scalable, small footprint platform was designed to
exceed the production of a 200L bioreactor with fewer
impurities while achieving 95% full capsids.
increase in high-purity
vector production
less impurities
less materials used
full capsids
Natural state of HEK293 cell growth
Improved transfection efficiency
Next-generation small footprint bioreactor
Cleaner harvest material with less DSP
Speed to clinic
Adaptation required for HEK293 cell growth
Extensive and costly development for high transfection efficiency
Large Stirred Tank Reactors (STRs) optimized for Mabs
Dirtier harvest material with extensive DSP
Slower advancement to clinics